Therapeutic strategies and clinical evolution of patients with infantile fibrosarcoma: a unique paediatric case series
Tóm tắt
Infantile fibrosarcoma is the most frequent soft tissue sarcoma in newborns or children under one year of age. This tumour often implies high local aggressiveness and surgical morbidity. The large majority of these patients carry the ETV6–NTRK3 oncogenic fusion. Hence, the TRK inhibitor larotrectinib emerged as an efficacious and safe alternative to chemotherapy for NTRK fusion-positive and metastatic or unresectable tumours. However, real-world evidence is still required for updating soft-tissue sarcoma practice guidelines. To report our experience with the use of larotrectinib in pediatric patients. Our case series shows the clinical evolution of 8 patients with infantile fibrosarcoma under different treatments. All patients enrolled in this study received informed consent for any treatment. Three patients received larotrectinib in first line. No surgery was needed with larotrectinib, which led to the rapid and safe remission of tumours, even in unusual anatomical locations. No significant adverse effects were observed with larotrectinib. Our case series supports that larotrectinib may be a therapeutic option for newborn and infant patients with infantile fibrosarcoma, especially in uncommon locations.
Tài liệu tham khảo
Orbach D, Sparber-Sauer M, Laetsch TW, Minard-Colin V, Bielack SS, Casanova M, et al. Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: international consensus and remaining controversies. Eur J Cancer. 2020;137:183–92.
Orbach D, Brennan B, De Paoli A, Gallego S, Mudry P, Francotte N, et al. Conservative strategy in infantile fibrosarcoma is possible: the European paediatric Soft tissue sarcoma study group experience. Eur J Cancer. 2016;57:1–9.
Forsythe A, Zhang W, Phillip Strauss U, Fellous M, Korei M, Keating K. A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors. Ther Adv Med Oncol. 2020;12:1758835920975613.
Looney A-M, Nawaz K, Webster RM. Tumour-agnostic therapies. Nat Rev Drug Discov. 2020;19:383–4.
Van Tilburg C, Albert C, Bielack S, Dubois S, Federman N, Geoerger B, et al. SIOP ABSTRACTS - O0112 / #485 Efficacy and safety of Larotrectinib in pediatric patients with non-central nervous system (CNS) tropomyosin receptor kinase (TRK) Fusion-positive cancer: an expanded dataset. Pediatr Blood Cancer. 2021;68:S54–S54.
U.S. Food and Drug Administration (FDA). VITRAKVI-Accelerated Approval (COR-NDAACTION-04) [Internet]. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf
European Medicines Agency (EMA). Vitrakvi [Internet]. 2019. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/vitrakvi
Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT). Ann Oncol. 2018;29:1895–902.
Lassen U. How I treat NTRK gene fusion-positive cancers. ESMO Open. 2019;4: e000612.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Soft Tissue Sarcoma Version 3. [Internet]. 2022. Available from: https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf
Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, et al. Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:1348–65.
Ferrari A, Spunt SL, Sparber-Sauer M, Walterhouse DO, Pajtler KW, Meyer WH, et al. Controversies and challenges in the management of paediatric non-rhabdomyosarcoma soft tissue sarcomas. Lancet Child Adolesc Heal. 2022;6:221–3.
Ferrari A, Brennan B, Casanova M, Corradini N, Berlanga P, Schoot RA, et al. pediatric non-rhabdomyosarcoma soft tissue sarcomas: standard of care and treatment recommendations from the European paediatric soft tissue sarcoma study group (EpSSG). Cancer Manag Res. 2022;14:2885.
Drilon A. TRK inhibitors in TRK fusion-positive cancers. Ann Oncol. 2019;30:viii23–30.
Yang JCH, Brose MS, Castro G, Kim ES, Lassen UN, Leyvraz S, et al. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib. BMC Cancer. 2022;22:625.
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731–9.